US20110262475A1 - Lyme disease vaccine - Google Patents
Lyme disease vaccine Download PDFInfo
- Publication number
- US20110262475A1 US20110262475A1 US12/990,079 US99007909A US2011262475A1 US 20110262475 A1 US20110262475 A1 US 20110262475A1 US 99007909 A US99007909 A US 99007909A US 2011262475 A1 US2011262475 A1 US 2011262475A1
- Authority
- US
- United States
- Prior art keywords
- seq
- borrelia
- ospc
- epitopes
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940042470 lyme disease vaccine Drugs 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 145
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 97
- 208000016604 Lyme disease Diseases 0.000 claims abstract description 92
- 101710105711 Outer surface protein C Proteins 0.000 claims abstract description 88
- 229920001184 polypeptide Polymers 0.000 claims abstract description 86
- 101710105714 Outer surface protein A Proteins 0.000 claims abstract description 84
- 241000589968 Borrelia Species 0.000 claims abstract description 80
- 230000000890 antigenic effect Effects 0.000 claims abstract description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 22
- 230000028993 immune response Effects 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 238000009739 binding Methods 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 abstract description 33
- 206010061591 Borrelia infection Diseases 0.000 abstract description 7
- 150000001413 amino acids Chemical class 0.000 description 37
- 241000589969 Borreliella burgdorferi Species 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 32
- 239000000203 mixture Substances 0.000 description 22
- 241001148605 Borreliella garinii Species 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 108700006640 OspA Proteins 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241001148604 Borreliella afzelii Species 0.000 description 8
- 229940099789 ospa protein Drugs 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108700023315 OspC Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000589970 Spirochaetales Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000238876 Acari Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- -1 substitution of A Chemical class 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 208000035145 Arthropod-borne disease Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010062488 Erythema migrans Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101800001707 Spacer peptide Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000004374 Tick Bites Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001449 borreliacidal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 101150045801 ospA gene Proteins 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention generally relates to a vaccine and diagnostic for Lyme disease.
- the invention provides a Lyme disease vaccine and diagnostic that includes linear Borrelia outer surface protein A (OspA) epitopes and/or Borrelia outer surface protein C (OspC) epitopes, usually from multiple distinct phyletic groups.
- OspA linear Borrelia outer surface protein A
- OspC Borrelia outer surface protein C
- Lyme disease is the most common arthropod-borne disease in North America and Europe, where in some areas up to 3% of the population is infected annually. Lyme disease is caused by the spirochetes Borrelia burgdorferi, B. garinii and B. afzelii. Transmission to mammals occurs through the bite of infected Ixodes ticks. Infection results in a multi-systemic inflammatory disease with early stage symptoms that may include erythema migrans, low-grade fever, arthralgia, myalgia, and headache. Late stage clinical manifestations can be severe and may include in part, arthritis and neurological complications. In addition, Lyme disease has significant socio-economic costs, manifested by reductions in outdoor recreational and social activities due to concerns about tick exposure.
- OspA Outer surface protein A
- LFA-1 human proteins
- the OspA protein from Borrelia burgdorferi has been epitope mapped by assessing the reactivity of sera generated during murine infection with recombinant OspA subfragments.
- the epitope map demonstrated several linear epitope-containing regions of OspA. While conformational epitopes of OspA have been mapped and described, linear epitopes have not previously been reported for use in a vaccine.
- the use of one or more of these small, defined epitope-containing sequences in a polypeptide vaccine formulation allows the avoidance of specific regions of OspA that have been implicated in vaccine-mediated adverse events when full-length OspA is used.
- the inclusion of linear epitopes from a plurality of phyletic groups of Borrelia results in a vaccine that provides broad protection against infection over large geographical areas.
- one or more defined epitope-containing sequences from the Borrelia OspC protein have been used in vaccine formulations.
- epitopes or epitope-containing sequences from multiple phyletic groups are utilized.
- the invention provides vaccine compositions which contain epitopes or epitope regions from both OspA and OspC.
- An isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26); and SEQ ID NO:
- the at least one linear epitope is selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; and SEQ ID NO: 18.
- the isolated recombinant or synthetic peptide or polypeptide may further comprise one or more amino acid sequences that are epitopes of Borrelia outer surface protein C (OspC), for example, one or more amino acid sequences that are epitopes of Borrelia OspC from an OspC loop 5 region or an OspC alpha helix 5 region, or both.
- OspC outer surface protein C
- the epitopes of OspC may be OspC types selected from the group consisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A,72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, and C.
- the one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73.
- the invention also provides a method for eliciting an immune response against Borrelia in an individual in need thereof.
- the method comprises the step of administering to the individual an isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA).
- OspA outer surface protein A
- the at least one linear epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; and SEQ ID NO: 18.
- the isolated recombinant or synthetic peptide or polypeptide may further comprise one or more amino acid sequences that are epitopes of Borrelia outer surface protein C (OspC), for example, one or more amino acid sequences that are epitopes of Borrelia OspC from an OspC loop 5 region or an OspC alpha helix 5 region, or both.
- OspC outer surface protein C
- the epitopes of OspC may be OspC types selected from the group consisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A, 72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, and C.
- the one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73.
- the invention further provides a method for ascertaining whether an individual has been exposed to or infected with Borrelia , or both.
- the method comprises the steps of 1) obtaining a biological sample from said individual; 2) exposing said biological sample to a recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ED NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID
- the recombinant or synthetic peptide or polypeptide further comprises one or more epitopes of Borrelia outer surface protein C (OspC), such as those having sequences as set forth in SEQ ID NOS: 65-73.
- OspC Borrelia outer surface protein C
- the invention further provides antibodies to a recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA) or outer surface protein C (OspC).
- the at least one linear epitope having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 1-27 (for OspA) and SEQ ID NOS: 65-73 (for OspC).
- the antibody is bactericidal for Borrelia spirochetes.
- the invention further provides an isolated recombinant or synthetic peptide or polypeptide comprising one or more epitopes from Borrelia outer surface protein A (OspA), said one or more epitopes being from an antigenic region selected from the group consisting of: antigenic region 221-240, antigenic region 17-67, antigenic region 94-144, and antigenic region 119-169.
- the isolated recombinant or synthetic peptide or polypeptide may further comprising one or more epitopes of Borrelia outer surface protein C (OspC).
- the invention also provides an isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein C (OspC).
- the at least one linear epitope may have an amino acid sequence selected from the group consisting of: SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; and SEQ ID NO: 73.
- the isolated recombinant or synthetic peptide or polypeptide may, in some embodiments, further comprise one or more epitopes of Borrelia outer surface protein A (OspA).
- FIG. 1 Alignment of the epitope-containing region of OspC protein sequences from all OspC types defined in this study. All sequences within OspC types that differ by more than one amino acid are indicated by a representative sequence. Identity threshold for shading is 80%. Secondary structural alpha helices and loops (corresponding to the B31 structure) are shown below the alignment (Kumaran, D., S. Eswaramoorthy, B. J. Lucas, S. Koide, J. J. Dunn, C. L. Lawson, and S. Swaminathan. 2001. Crystal structure of outer surface protein C (OspC) from the Lyme disease spirochete, Borrelia burgdorferi. EMBO J. 20:971-978).
- OspC outer surface protein C
- FIG. 2A-C General epitope locations for OspC constructs.
- A Construct A (SEQ ID NO: 62);
- B Construct B (SEQ ID NO: 63),
- C Construct C (SEQ ID NO: 64).
- FIG. 3 Schematic of subfragments used to map linear epitopes in OspA. The initial screening of ⁇ 50 amino acid subfragments was followed by targeted screening of overlapping ⁇ 20 amino acid fragments to more accurately define the epitope location. Fragments detected by one or more mouse sera are denoted by a (+).
- FIG. 4 Western blot mapping of OspA demonstrates several linear epitopes. r-OspA subfragments were screened with sera from mice infected for 6 weeks with one of three B. burgdorferi strains. Secondary antibody detection was IgG-specific. While all mice generated an anti-OspA response, as demonstrated by the full length protein (17-273), only a subset recognized linear epitopes on the tested subfragments. Of those fragments recognized, the most frequently and strongly recognized epitope was localized between amino acids 221 and 240.
- FIG. 5 Alignment of OspA sequences from the three B. burgdorferi strains used to infect mice for OspA epitope mapping.
- B31Mi SEQ ID NO: 74; B331, SEQ ID NO: 75; LDP74, SEQ ID NO: 76.
- FIG. 6 Structural representation of OspA highlighting a linear epitope-containing region.
- a ribbon diagram of OspA crystal structure (1FJ1) highlights amino acids 221-240 (gray) that contain a mapped linear epitope.
- the box surrounds the three loop regions that define the previously described protective Lk-2 conformational epitope.
- the protein N-terminus is at the bottom of the diagram.
- the present invention is based on the identification and characterization of linear peptide epitopes from Borrelia OspA protein. Identification of these epitopes has made possible the design and construction of chimeric (fusion) polypeptides that can be used as vaccines against Lyme disease, or as diagnostic tools.
- the polypeptides which arc generally isolated and/or purified, comprise at least one copy of an epitope from one of four classes of Borrelia OspA cpitopes or antigenic regions. The four classes are organized based on the amino acid sequences numbering of OspA Borrelia burgdorferi strain B31M1, as follows:
- Class I is from Borrelia burgdorferi strain B31M1: Class I: STLTITVNSKKTKDLVFTKE (SEQ ID NO: 1), which corresponds to residues 221-240 of OspA protein from B. burgdorferi.
- Additional corresponding or analogous type specific (i.e. phyletically related) exemplary Class I sequences that may be used in the practice of the invention include the following:
- the prototype Class II sequence from Borrelia burgdorferi strain B31M1 is: Class II: CKQNVSSLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLEL KGTS (SEQ ID NO: 19), which corresponds to residues 17-67 of OspA protein from B. burgdorferi.
- the prototype Class III sequence from Borrelia burgdorferi strain B31M1 is: Class III: LGQTTLEVFKEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRADGTR (SEQ ID NO: 22), which corresponds to residues 94-144 of OspA protein from B. burgdorferi.
- the prototype Class IV sequence from Borrelia burgdorferi strain B31M1 is: Class IV: KSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGYVLEG (SEQ ID NO: 25), which corresponds to residues 119-169 of OspA protein from B. burgdorferi.
- Additional exemplary Class II, II and IV type-specific sequences that may be used in the practice of the invention include those depicted in Table 2.
- the sequences in Table 2 (SEQ ID NOS: 19-27) are exemplary, in that a phylogenetic analysis of Borrelia OspA at the indicated regions would generate additional potential sequences for use in the practice of the invention (i.e. additional sequences from other Borrelia species, strains or types).
- afzelii CAA59724.1 24 LSKPTFELFKGDGETLVSRKVS SKDKTSTDEMFNEKGELSAKTM TRENGTK Amino acids 119-169 B. burgdorferi NP045688.1 25 KSSTEEKFNEKGEVSEKIITRA DGTRLEYTGIKSDGSGKAKEVL KGYVLEG Amino acids 119-169 B. garinii CAA56545.1 26 KSSTEEKFNEKGETSEKTIVRA NGTRLEYTDIKSDGSGKAKEVL KDFTLEG Amino acids 119-169 B. afzelii CAA59724.1 27 KTSTDEMFNEKGELSAKTMTRE NGTKLEYTEMKSDGTGKAKEVL KNFTLEG
- linear epitopes advantageously avoids exposing the vaccine recipient to regions of OspA that have been implicated in putative adverse vaccine effects.
- the inclusion of a plurality of these linear sequences provides broad coverage against the development of Lyme disease for individuals over a broad geographical area.
- the polypeptides of the invention enable detection of exposure to or infection with Borrelia of most important phyletic types over a broad geographical area.
- the vaccine and/or diagnostic compositions can be “tuned” if desired, to represent one or more, but not all, geographical regions. For example, a vaccine or diagnostic developed for use in North America might contain only sequences derived from B.
- polypeptides containing one or more linear OspA epitopes or antigenic regions as described herein may also include one or more OspC epitopes or antigenic regions, as described in detail below.
- an antigenic chimeric (or fusion) polypeptide of the invention comprises one or more amino acid sequence from Class I, such as those set forth in, for example, SEQ ID NOS: 1 and 2.
- SEQ ID NOS: 1 and 2 amino acid sequence from Class I
- one or more copies of two or more Class I sequences will be included, and each distinct sequence may be present in the polypeptide one or more time, i.e. multiple copies of one or more of the sequences set forth in, for example, SEQ ID NOS: 1 and 2 are included.
- the Class I sequences may be included, and for each separate sequence that is included, that sequence may be present in from about 2 to about 12 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) or more copies.
- Individual copies of the sequence may be separated by linker sequences (described below), although this need not always be the case, i.e. copies of the same or different antigenic regions may be contiguous in the polypeptide chain.
- one or more of the amino acid sequences set forth in or represented by the Class II or Class III or Class IV antigenic regions are included in the antigenic polypeptides of the invention.
- one or more of the peptides may be present in the antigenic polypeptide, and, for each distinct sequence that is present, multiple copies(e.g. from about 2 to about 12) may be included. Individual copies of the sequence may be separated by linker sequences, although this need not always be the case.
- mixtures of one or more copies of one or more Class I, Class II, Class III and/or Class IV antigenic regions are present in the antigenic polypeptides of the invention.
- the polypeptide includes a mixture antigenic regions from any of the four classes.
- Each of the sequences that is included may be present in one copy or, more frequently, as multiple copies.
- the individual sequences may be present in any order.
- one segment or section of the polypeptide may include multiple copies of e.g. SEQ ID NO: 1, while another section of the same polypeptide includes multiple copies of e.g. SEQ ID NO: 2, and so on.
- the sequences of e.g. SEQ ID NO: 1 and e.g. SEQ ID NO: 2 may alternate along the polypeptide chain so that the sequences are, in effect, interspersed amongst each other within the primary sequence of the polypeptide.
- OspC Borrelia proteins
- the invention thus provides chimeric polypeptides or proteins that comprise, one or more epitopes from OspC.
- Exemplary OspC epitopes include but are not limited to linear epitopes from the loop 5 and/or alpha helix 5 regions.
- the loop 5 region or domain of OspC is the region which includes residues that align with residues 131 to 159 of strain B31 (type A) OspC sequences (together with secondary structural elements such as a portion of alpha helix 3, loop 5, and alpha helix 4, as defined by Kumaran et al.
- the alpha helix 5 region/domain of OspC is the region which includes residues that align with amino acids 160 to 200 of the strain B31 (OspC type A) sequence and the C-terminal portion of the protein, amino acids 201-210 of the B31 sequence, as well as secondary structural elements including a portion of loop 6, alpha helix 5, and the unstructured C-terminal domain, as defined by Kumaran et al. (2001).
- one or more peptides encompassing epitopes located within the primary linear sequence of OspC proteins from residues 131 to 200 may be included in the immunogenic polypeptides of the invention, the polypeptides of the invention.
- Exemplary OspC regions from which epitopes may be selected are shown in FIG. 1 , where the sequences corresponding to residues 131 to 200 of type A OspC from several Borrelia types are listed.
- One or more epitopes may be selected for inclusion, so that an entire 131-200 (or even 131-210 C-terminal) region encompassing several epitopes may be used.
- fragments of the 131-200 region may be employed, e.g. any contiguous sequence of from about 10 to about 50 amino acids.
- One or more of such contiguous sequences may be used in the practice of the invention, with preferable sequences being those corresponding to about amino acids 136 to 150 and about amino acids 168-203 of alpha helix 5.
- Constructs A, B and C differ in that the sequences contained therein are from different phyletic types. For example, as shown in FIG. 2A , Construct A contains sequences from Types A, B, K, I, H, N, C, M and D of B. burgdorferi. In addition, for each of Constructs A, B and C, various versions or variations have been developed.
- the versions differ, for example, by the inclusion or exclusion of an intervening Helix-4/Loop6 sequence, by the order of the individual epitopes, and by other exclusions and or additions, etc.
- Exemplary variations of Constructs A, B and C are shown in Table 3.
- At least two of the OspC epitopes included in the chimeric polypeptide are from different OspC types that are associated with invasive infection.
- antigenic epitopes representing from about 2 to about 20, and preferably from about 6 to about 10, different OspC types are included in a chimeric protein.
- such a multivalent (polyvalent) recombinant chimeric protein elicits broad protection against infection with Borrelia spirochetes expressing the OspC types that correspond to those in the chimeric protein, i.e. those Borrelia that are highly infective.
- the immunodominant OspC epitopes are selected from OspC types Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A,72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, C.
- epitopes from many combinations of OspC types may be used, so long as the resulting chimera produces a suitable immune response and/or
- OspC epitopes which may optionally be combined with OspA epitopes of Classes I-IV
- suitable combinations of OspC epitopes include but are not limited to: 1) E, N, I, C, A, B, K, D; 2) A, B, K, D, E, N, C; 3) I, C, A, B, K, D; and 4) C, A, B, K, D.
- both the OspC loop 5 and OspC alpha helix 5 regions will be included.
- an “E, N, I, C, A, B, K, D” construct may contain both the loop 5 and helix 5 regions of each of OspC types E, N, I, C, A, B, K, and D.
- the loop 5 region of type A and the alpha helix 5 regions of E, N, I, C, B, K, and D may be included; or only the loop 5 region for each OspC type may be included; or only the alpha helix 5 region; or other combinations may be included (e.g. loop 5 region of types E, N, I, and C and the alpha helix 5 region of types A, B, K, and D. Many such combinations will occur to those of skill in the art, and all such variations are intended to be encompassed herein.
- one or more of the sequences represented by OspA Classes I-IV are present in an antigenic polypeptide which also includes antigenic sequences of OspC as described above.
- peptide sequences may be included in the peptides and polypeptides of the invention.
- sequences include but are not limited to antigenic peptide sequences such as linker sequences which in and of themselves are antigenic.
- amino acid sequences that are chosen for inclusion in the peptides and polypeptides of the invention correspond exactly to the primary amino acid sequence of the original or native sequences of an OspA (or OspC) protein, this need not always be the case.
- the amino acid sequence of an epitope that is included in the peptides and polypeptides of the invention may be altered somewhat and still be suitable for use in the present invention. For example, certain conservative amino acid substitutions may be made without having a deleterious effect on the ability of the peptides and polypeptides to elicit an immune response.
- substitutions or alterations of the sequences of the peptides and polypeptides that are disclosed herein are intended to be encompassed by the present invention, so long as the resulting peptides and polypeptides still function to elicit a suitable immune response.
- amino acid sequences that are included in the chimeric proteins of the invention need not encompass a full length native peptide or polypeptide.
- truncated versions of amino acid sequences that are known to be or to contain antigenic peptides and/or polypeptides may, for a variety of reasons, be preferable for use in the practice of the invention, so long as the criteria set forth for an epitope is fulfilled by the sequence.
- Amino acid sequences that are so substituted or otherwise altered may be referred to herein as “based on” or “derived from” the original wild type or native sequence.
- the OspA or OspC proteins from which the linear epitopes are “derived” or on which the linear epitopes are “based” are the OspA or OspC proteins as they occur in nature.
- These natural OspA/OspC proteins may alternatively be referred to as native or wildtype proteins.
- Such changes to the primary sequence may be introduced for any of a variety of reasons, for example, to eliminate or introduce a protease cleavage site, to increase or decrease solubility, to promote or discourage intra- or inter-molecular interactions such as folding, ionic interactions, salt bridges, etc, which might otherwise interfere with the presentation and accessibility of the individual epitopes along the length of a peptide or polypeptide. All such changes are intended to be encompassed by the present invention, so long as the resulting amino acid sequence functions to elicit a protective antibody response in a host to whom it is administered.
- substituted sequences will be at least about 50% identical to the corresponding sequence in the native protein, preferably about 60 to 70, or even 70 to 80, or 80 to 90% identical to the wild type sequence, and preferably about 95, 96, 97, 98, 99, or even 100% identical to a native OspA (or OspC) sequence.
- the reference native OspA or OspC sequence may be from any suitable type of Borrelia , e.g. from any Borrelia which is known to infect mammals.
- the individual linear epitopes in the chimeric vaccinogen are separated from one another by intervening sequences that are more or less neutral in character, i.e. they do not in and of themselves elicit an immune response to Borrelia .
- sequences may or may not be present between the epitopes of a chimera. If present, they may, for example, serve to separate the epitopes and contribute to the steric isolation of the epitopes from each other.
- sequences may be simply artifacts of recombinant processing procedures, e.g. cloning procedures.
- Such sequences are typically known as linker or spacer peptides, many examples of which are known to those of skill in the art.
- LINKER a program to generate linker sequences for fusion proteins. Protein Engineering 13(5): 309-312, which is a reference that describes unstructured linkers. Structured (e.g. helical) sequence linkers may also be designed using, for example, existing sequences that are known to have that secondary structure, or using basic known biochemical principles to design the linkers. In addition, other elements may be present in the chimeric proteins, for example leader sequences or sequences that “tag” the protein to facilitate purification or detection of the protein, examples of which include but are not limited to histidine tags, detection tags (e.g.
- chimeric proteins may be chemically modified, e.g. by amidation, sulfonylation, lipidation, or other techniques that are known to those of skill in the art.
- the invention further provides nucleic acid sequences that encode the chimeric proteins of the invention.
- nucleic acids include DNA, RNA, and hybrids thereof, and the like.
- the invention comprehends vectors which contain or house such coding sequences. Examples of suitable vectors include but are not limited to plasmids, cosmids, viral based vectors, expression vectors, etc. In a preferred embodiment, the vector will be a plasmid expression vector.
- the chimeric polypeptides of the invention may be produced by any suitable method, many of which are known to those of skill in the art. For example, they may be chemically synthesized, or produced using recombinant DNA technology (e.g. in bacterial cells, in cell culture (mammalian, yeast or insect cells), in plants or plant cells, or by cell-free prokaryotic or eukaryotic-based expression systems, by other in vitro systems, etc.). In some embodiments, the polypeptides are produced using chemical synthesis methods.
- the present invention also provides compositions for use in eliciting an immune response.
- the compositions may be utilized as vaccines to prevent or treat Borrelia infection, particularly when manifested as Lyme disease (Lyme borreliosis).
- Lyme disease Lyme borreliosis
- eliciting an immune response we mean that administration of the antigen causes the synthesis of specific antibodies (at a titer as described above) and/or cellular proliferation, as measured, e.g. by 3 H thymidine incorporation, or by other known techniques.
- vaccine we mean a chimeric or fusion polypeptide that elicits an immune response which results in protection of an organicism against challenge with Borrelia .
- the protective response either wholly or partially prevents or arrests the development of symptoms related to Borrelia infection (i.e. the symptoms of Lyme disease), in comparison to a non-vaccinated (e.g. adjunct alone) control organisms, in which disease progression is not prevented.
- the compositions include one or more isolated and substantially purified chimeric peptides or polypeptides as described herein, and a pharmacologically suitable carrier.
- the chimeric polypeptides or proteins in the composition may be the same or different, i.e. the composition may be a “cocktail” of different chimeras, or a composition containing only a single type of chimera.
- the preparation of such compositions for use as vaccines is well known to those of skill in the art.
- compositions are prepared either as liquid solutions or suspensions, however solid forms such as tablets, pills, powders and the like are also contemplated. Solid forms suitable for solution in, or suspension in, liquids prior to administration may also be prepared.
- the preparation may also be emulsified.
- the active ingredients may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredients. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like, or combinations thereof.
- the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like.
- the vaccine preparations of the present invention may further comprise an adjuvant, suitable examples of which include but are not limited to Seppic, Quil A, Alhydrogel, etc. If it is desired to administer an oral form of the composition, various thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders and the like may be added.
- the composition of the present invention may contain any such additional ingredients so as to provide the composition in a form suitable for administration.
- the final amount of chimeric protein in the formulations may vary. However, in general, the amount in the formulations will be from about 0.01-99%, weight/volume.
- the methods involve administering a composition comprising a chimeric recombinant protein in a pharmacologically acceptable carrier to a mammal.
- the mammal may be a human, but this need not always be the case, as veterinary applications of this technology are also contemplated.
- the vaccine preparations of the present invention may be administered by any of the many suitable means which are well known to those of skill in the art, including but not limited to by injection, inhalation, orally, intranasally, by ingestion of a food product containing the chimeric protein, etc.
- the mode of administration is subcutaneous or intramuscular.
- the compositions may be administered in conjunction with other treatment modalities such as substances that boost the immune system, various anti-bacterial chemotherapeutic agents, antibiotics, and the like.
- the present invention provides methods to elicit an immune response to Borrelia and to vaccinate against Borrelia infection in mammals.
- the mammal is a human
- the preparations may also be used for veterinary purposes. Examples include but are not limited to companion “pets” such as dogs, cats, etc.; food source, work and recreational animals such as cattle, horses, oxen, sheep, pigs, goats, and the like; or even wild animals that serve as a reservoir of Borrelia (e.g. mice, deer, etc).
- the invention also provides a diagnostic and a method for using the diagnostic to identify individuals who have antibodies to the epitopes contained within the chimeric polypeptides of the invention.
- a biological sample from an individual e.g. a human, a deer, or other mammals susceptible to infection by Borrelia spirochetes
- Borrelia spirochetes suspected of having been exposed to Borrelia , or at risk for being exposed to Borrelia
- the chimeric proteins of the invention is contacted with the chimeric proteins of the invention.
- the presence or absence of a binding reaction between the chimeric protein and antibodies in the biological sample is detected.
- a positive result i.e. binding occurs, thus antibodies are present indicates that the individual has been exposed to and/or is infected with Borrelia .
- diagnostic aspects of the invention are not confined to clinical use or home use, but may also be valuable for use in the laboratory as a research tool, e.g. to identify Borrelia spirochetes isolated from ticks, to investigate the geographical distribution of Borrelia species and strains, etc.
- the present invention also encompasses antibodies to the epitopes and/or to the chimeric polypeptides disclosed herein.
- Such antibodies may be polyclonal, monoclonal or chimeric, and may be generated in any manner known to those of skill in the art.
- the antibodies are bactericidal ( borrelia cidal), i.e. exposure of Borrelia spirochetes to the antibodies causes death of the spirochetes.
- Such antibodies may be used in a variety of ways, e.g. as detection reagents to diagnose prior exposure to Borrelia , as a reagent in a kit for the investigation of Borrelia , to treat Borrelia infections, etc.
- antigen fragments or antigenic sequences or epitopes may be identified by their ability, when included in a chimeric protein, to elicit suitable antibody production to the epitope in a host to which the chimeric protein is administered.
- suitable antibody production is characterized by an antibody titer in the range of from about 100 to about 100,000, and preferably in the range of from about 10,000 to about 10,000,000.
- the “titer” should be about three times the background level of binding.
- reactivity in a test should be at least three times greater than reactivity detected in serum from uninfected individuals.
- the antibody response is protective, i.e. prevents or lessens the development of symptoms of disease in a vaccinated host that is later exposed to Borrelia , compared to an unvaccinated host.
- Fragments of the outer surface protein A (OspA) gene were amplified by PCR using high fidelity DNA polymerase (Phusion HF, New England Biolabs), and the amplicons purified by agarose gel electrophoresis and gel extraction. Overhangs were generated by treatment with T4 polymerase to allow ligase-independent annealing to the pET-32 Ek/LIC vector. The annealed vector was transformed into Escherichia coli, and the transformants were selected for ampicillin resistance, and were screened for the presence of the OspA gene fragment by PCR. Plasmids were then extracted from the transformants and the sequence confirmed by DNA sequencing (MWG Biotech). The plasmids were then used to transform E. coli BL21 (DE3) cells for protein production.
- BL21(DE3) cells were grown at 37° C. to an OD 600 of 0.5, then 1 mM IPTG was added to induce protein expression, and the cells were maintained at 37° C. for an additional 3 hours.
- the pET-32 Ek/LIC vector encodes a 17.1 kDa N-terminal protein tagging sequence which includes a hexahistidine motif that was used to purify the r-proteins by Ni—NTA nickel affinity chromatography, according to the manufacturer's protocol (Qiagen). The purified proteins were quantified by the bicinchoninic acid assay (Pierce).
- B31MI, LDP74, and B331 were grown to late log phase in BSK-H medium (Sigma). The cells were washed with fresh medium, quantified by microscopy, and diluted in BSK-H medium to 10 4 cells per 0.1 mL of medium.
- Strain C3H/HeJ mice were infected with 10 4 cells by subcutaneous injection between the scapulae, with 5 mice infected with each spirochete strain. The mice were bled at week 6 by tail nick, and infection was confirmed by culture of a 2 mm ear punch biopsy. Serum was prepared from the infected mouse blood samples, and will be referred to hereafter as infection serum.
- the blots were washed, incubated with a chemiluminescent substrate (Supersignal West Pico; Pierce), and exposed to film. When reactive OspA fragments were determined, a series of smaller overlapping subfragments was made to further resolve the location of the linear epitope ( FIG. 3 ).
- a chemiluminescent substrate Supersignal West Pico; Pierce
- the full length ospA gene from the Borrelia strains used to produce infection sera were PCR amplified and cloned into the pET-46 Ek/LIC vector as described above, and the DNA sequences were aligned and compared.
- the 204 full length OspA sequences from the Lyme spirochetes B. burgdorferi, B. garinii, and B. afzelii that are available in the NCBI databases were aligned and analyzed for polymorphisms in the epitope containing regions. This was done by multisequence alignment using ClustalX, and generation of neighbor joining phylogenetic trees.
- a western blot-based search for linear B-cell epitopes on OspA revealed several amino acid sequences that were reactive with antibodies generated during murine infection ( FIG. 4 ).
- the reactive subfragments are located at the N-terminus (amino acids 17-67; noted in a single mouse), within a central single layer beta-sheet (amino acids 94-144, and 119-169; seen in multiple mice), and within a membrane-distal loop (amino acids 194-246 and 220-273; highly reactive in multiple mice).
- High resolution mapping of the beta-sheet epitope containing region failed to further localize the epitope.
- the most reactive linear epitope was found in the membrane distal loop, and subsequent high resolution mapping localized it to amino acids 221-240.
- the pattern of reactivity varied somewhat in intensity between mice, but was observed in sera from mice infected with each of the three test Borrelia strains.
- OspA protein was expressed only for a short time during the infection, which may account for the variability in the intensity of responsiveness between mice. This apparent variability may be enhanced by the IgG-specific screening technique, requiring the B-cells of the infected mice to progress to a more mature immune response and undergo immunoglobulin heavy chain class switching.
- the large degree of intraspecies conservation at the mapped epitope-containing regions is of particular advantage in development of a peptide or chimeric vaccine.
- B. burgdorferi is the only species associated with Lyme disease in North America, the occurrence of only a limited number of phylogenetic clades of OspA is particularly advantageous.
- the number of major clades is also limited, with only two major antigenically distinct clades representing the large majority of the 221-240 epitope containing region.
- Borrelia afzelii which occurs only in Europe and Asia, is limited to a single clade at this region, and B.
- garinii has approximately 6 clades, several of which are closely related, though it is not yet known if they are antigenically cross-reactive. It is clear that in order for broad protection to be achieved by a peptide vaccine approach, the use of a single OspA epitope sequence is not possible. For that reason, the development of a multi-epitope chimeric vaccine based on OspA epitope variants or on a combination of epitope variants of OspA and OspC is highly desirable. In addition, a significant advantage to the use of defined epitope containing sequences is the ability to avoid segments of the OspA molecule that have been reported to be associated with development of autoimmune responses. While there is disagreement in the literature as to the incidence of these responses caused by anti-OspA antibodies or anti-OspA immune responses, it is advantageous to avoid those portions of OspA that have been implicated ( FIG. 6 ).
- this chimeric polypeptide construct comprising at least one 221-240 epitope containing region, and usually two or more 221-240 epitope containing regions from of different phyletic types, is found to elicit a robust immune response, and to provide protection from the development of Lyme disease.
Abstract
Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.
Description
- 1. Field of the Invention
- The invention generally relates to a vaccine and diagnostic for Lyme disease. In particular, the invention provides a Lyme disease vaccine and diagnostic that includes linear Borrelia outer surface protein A (OspA) epitopes and/or Borrelia outer surface protein C (OspC) epitopes, usually from multiple distinct phyletic groups.
- 2. Background of the Invention
- Lyme disease is the most common arthropod-borne disease in North America and Europe, where in some areas up to 3% of the population is infected annually. Lyme disease is caused by the spirochetes Borrelia burgdorferi, B. garinii and B. afzelii. Transmission to mammals occurs through the bite of infected Ixodes ticks. Infection results in a multi-systemic inflammatory disease with early stage symptoms that may include erythema migrans, low-grade fever, arthralgia, myalgia, and headache. Late stage clinical manifestations can be severe and may include in part, arthritis and neurological complications. In addition, Lyme disease has significant socio-economic costs, manifested by reductions in outdoor recreational and social activities due to concerns about tick exposure.
- The antigen used in first generation Lyme disease vaccines (e.g. LYMErix) was Outer surface protein A (OspA). OspA is only expressed by spirochetes in ticks, thus anti-OspA bactericidal activity occurs in the vector. However, a major drawback to the use of full-length OspA was the potential (whether real or perceived) for adverse events secondary to vaccination, such as the development of arthritis caused by immunological cross-reactivity with human proteins (e.g. LFA-1). This was a major factor in the withdrawal from the market of the original OspA-based LYMErix vaccine.
- U.S. Pat. 6,248,562 (Jun. 19, 2001) to Dunn and Luft describes chimeric Borrelia proteins that can be used as immunodiagnostic reagents and vaccine immunogens against Borrelia infection.
- U.S. Pat. Nos. 6,872,550 and 6,486,130 (Mar. 29, 2005, and Nov. 26, 2002, respectively) both to Livey, describe constructs for use a vaccines against Lyme disease.
- U.S. Pat. No. 7,008,625 (Mar. 7, 2006) to Dattwyler et al. discloses chimeric Borrelia proteins that can be used as immunodiagnostic reagents and vaccine immunogens against Borrelia infection
- The publication “Recombinant Chimeric Borrelia Proteins for Diagnosis of Lyme Disease” (Maria J. C. Gomes-Solecki et al. 2000. J. Clin. Microbiol., 38: 2530-2535) also describes recombinant chimeric proteins.
- Despite the above-referenced technologies, to date the prior art has failed to provide an efficacious vaccine for use in the prevention and/or treatment of Lyme disease.
- In order to address prior art problems with Lyme disease vaccines, the OspA protein from Borrelia burgdorferi has been epitope mapped by assessing the reactivity of sera generated during murine infection with recombinant OspA subfragments. The epitope map demonstrated several linear epitope-containing regions of OspA. While conformational epitopes of OspA have been mapped and described, linear epitopes have not previously been reported for use in a vaccine. The use of one or more of these small, defined epitope-containing sequences in a polypeptide vaccine formulation allows the avoidance of specific regions of OspA that have been implicated in vaccine-mediated adverse events when full-length OspA is used. The inclusion of linear epitopes from a plurality of phyletic groups of Borrelia results in a vaccine that provides broad protection against infection over large geographical areas.
- In addition, in other embodiments of the invention, one or more defined epitope-containing sequences from the Borrelia OspC protein have been used in vaccine formulations. Typically, epitopes or epitope-containing sequences from multiple phyletic groups are utilized.
- Finally, the invention provides vaccine compositions which contain epitopes or epitope regions from both OspA and OspC.
- It is an object of the
invention 1. An isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26); and SEQ ID NO: 27. - In one embodiment, the at least one linear epitope is selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; and SEQ ID NO: 18.
- The isolated recombinant or synthetic peptide or polypeptide may further comprise one or more amino acid sequences that are epitopes of Borrelia outer surface protein C (OspC), for example, one or more amino acid sequences that are epitopes of Borrelia OspC from an
OspC loop 5 region or anOspC alpha helix 5 region, or both. The epitopes of OspC may be OspC types selected from the group consisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A,72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, and C. In some embodiments, the one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73. - The invention also provides a method for eliciting an immune response against Borrelia in an individual in need thereof. The method comprises the step of administering to the individual an isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA). The at least one linear epitope having an amino acid sequence selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26); and SEQ ID NO: 27. In some embodiments, the at least one linear epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; and SEQ ID NO: 18. According to some embodiments of the method, the isolated recombinant or synthetic peptide or polypeptide may further comprise one or more amino acid sequences that are epitopes of Borrelia outer surface protein C (OspC), for example, one or more amino acid sequences that are epitopes of Borrelia OspC from an
OspC loop 5 region or anOspC alpha helix 5 region, or both. The epitopes of OspC may be OspC types selected from the group consisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A, 72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, and C. In some embodiments, the one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73. - The invention further provides a method for ascertaining whether an individual has been exposed to or infected with Borrelia, or both. The method comprises the steps of 1) obtaining a biological sample from said individual; 2) exposing said biological sample to a recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ED NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26); and SEQ ID NO: 27; and 3) determining whether antibodies in the biological sample bind to the recombinant or synthetic peptide or polypeptide, wherein detection of antibody binding is indicative of prior exposure to or infection with Borrelia. In some embodiments of this method, the recombinant or synthetic peptide or polypeptide further comprises one or more epitopes of Borrelia outer surface protein C (OspC), such as those having sequences as set forth in SEQ ID NOS: 65-73.
- The invention further provides antibodies to a recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA) or outer surface protein C (OspC). The at least one linear epitope having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 1-27 (for OspA) and SEQ ID NOS: 65-73 (for OspC). In some embodiments, the antibody is bactericidal for Borrelia spirochetes.
- The invention further provides an isolated recombinant or synthetic peptide or polypeptide comprising one or more epitopes from Borrelia outer surface protein A (OspA), said one or more epitopes being from an antigenic region selected from the group consisting of: antigenic region 221-240, antigenic region 17-67, antigenic region 94-144, and antigenic region 119-169. The isolated recombinant or synthetic peptide or polypeptide may further comprising one or more epitopes of Borrelia outer surface protein C (OspC).
- The invention also provides an isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein C (OspC). The at least one linear epitope may have an amino acid sequence selected from the group consisting of: SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; and SEQ ID NO: 73. The isolated recombinant or synthetic peptide or polypeptide may, in some embodiments, further comprise one or more epitopes of Borrelia outer surface protein A (OspA).
-
FIG. 1 . Alignment of the epitope-containing region of OspC protein sequences from all OspC types defined in this study. All sequences within OspC types that differ by more than one amino acid are indicated by a representative sequence. Identity threshold for shading is 80%. Secondary structural alpha helices and loops (corresponding to the B31 structure) are shown below the alignment (Kumaran, D., S. Eswaramoorthy, B. J. Luft, S. Koide, J. J. Dunn, C. L. Lawson, and S. Swaminathan. 2001. Crystal structure of outer surface protein C (OspC) from the Lyme disease spirochete, Borrelia burgdorferi. EMBO J. 20:971-978). -
FIG. 2A-C . General epitope locations for OspC constructs. A, Construct A (SEQ ID NO: 62); B, Construct B (SEQ ID NO: 63), C, Construct C (SEQ ID NO: 64). -
FIG. 3 . Schematic of subfragments used to map linear epitopes in OspA. The initial screening of ˜50 amino acid subfragments was followed by targeted screening of overlapping ˜20 amino acid fragments to more accurately define the epitope location. Fragments detected by one or more mouse sera are denoted by a (+). -
FIG. 4 . Western blot mapping of OspA demonstrates several linear epitopes. r-OspA subfragments were screened with sera from mice infected for 6 weeks with one of three B. burgdorferi strains. Secondary antibody detection was IgG-specific. While all mice generated an anti-OspA response, as demonstrated by the full length protein (17-273), only a subset recognized linear epitopes on the tested subfragments. Of those fragments recognized, the most frequently and strongly recognized epitope was localized between amino acids 221 and 240. -
FIG. 5 . Alignment of OspA sequences from the three B. burgdorferi strains used to infect mice for OspA epitope mapping. B31Mi, SEQ ID NO: 74; B331, SEQ ID NO: 75; LDP74, SEQ ID NO: 76. -
FIG. 6 . Structural representation of OspA highlighting a linear epitope-containing region. A ribbon diagram of OspA crystal structure (1FJ1) highlights amino acids 221-240 (gray) that contain a mapped linear epitope. The box surrounds the three loop regions that define the previously described protective Lk-2 conformational epitope. The protein N-terminus is at the bottom of the diagram. - The present invention is based on the identification and characterization of linear peptide epitopes from Borrelia OspA protein. Identification of these epitopes has made possible the design and construction of chimeric (fusion) polypeptides that can be used as vaccines against Lyme disease, or as diagnostic tools. The polypeptides, which arc generally isolated and/or purified, comprise at least one copy of an epitope from one of four classes of Borrelia OspA cpitopes or antigenic regions. The four classes are organized based on the amino acid sequences numbering of OspA Borrelia burgdorferi strain B31M1, as follows:
- Class I: Antigenic region 221-240;
- Class II: Antigenic region 17-67;
- Class III: Antigenic region 94-144; and
- Class IV: Antigenic region 119-169.
- The prototype Class I sequence is from Borrelia burgdorferi strain B31M1: Class I: STLTITVNSKKTKDLVFTKE (SEQ ID NO: 1), which corresponds to residues 221-240 of OspA protein from B. burgdorferi. Additional corresponding or analogous type specific (i.e. phyletically related) exemplary Class I sequences that may be used in the practice of the invention include the following:
-
TABLE 1 Sequence variants at the 221-240 epitope containing region. SEQ Accession ID Species number NO: Sequence B. burgdorferi NP045688.1 1 STLTITVNSKKTKDLVFTKE B. burgdorferi CAB64758.1 2 STLTIIVDSKNKTKLVFTKQ B. burgdorferi CAA56544.1 3 STLTISKNRTKTKQLVFTKE B. burgdorferi CAA01705.1 4 STLTISANSKKTKDLVFLTN B. burgdorferi CAR95557.1 5 STLTITVNNKKTKALVFTKQ B. burgdorferi and ABF29588.1 6 STLTISVNSKKTTQLVFTKQ B. afzelii CAA44092.1 B. burgdorferi and AAB23810.1 7 STLTISVNSKKTKNIVFTKE B. garinii AAT93773.1 B. burgdorferi and CAA82328.1 8 STLTISVNSQKTKNLVFTKE B. garinii CAA56546.1 B. garinii ACD02017.1 9 NTLTVSADSKKIKDFVFLTD B. garinii ABF29554.1 10 STLTISKNSQKTKQLVFTKE B. garinii AA091930.1 11 STLTISAKNKKTKDLVFTKQ B. garinii AAR96307.1 12 STLKISKNSKKTKQLVFTKE B. garinii AA091932.1 13 STLTISAKSKKTKDLVFTKQ B. garinii ACD02015.1 14 STLTISANNKKTKDLVFTKQ B. garinii AAR96306.1 15 KTLTVSADSKKIKDFVFLTD B. garinii AAP94131.1 16 STLTISAKNKKTTDLVFTKQ B. garinii ABF29567.1 17 STLTISKNSRKTKQLVFTKE B. garinii AAP94130.1 18 STLTISVNSRKTKNLVFTKE - The prototype Class II sequence from Borrelia burgdorferi strain B31M1 is: Class II: CKQNVSSLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLEL KGTS (SEQ ID NO: 19), which corresponds to residues 17-67 of OspA protein from B. burgdorferi.
- The prototype Class III sequence from Borrelia burgdorferi strain B31M1 is: Class III: LGQTTLEVFKEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRADGTR (SEQ ID NO: 22), which corresponds to residues 94-144 of OspA protein from B. burgdorferi.
- The prototype Class IV sequence from Borrelia burgdorferi strain B31M1 is: Class IV: KSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGYVLEG (SEQ ID NO: 25), which corresponds to residues 119-169 of OspA protein from B. burgdorferi. Additional exemplary Class II, II and IV type-specific sequences that may be used in the practice of the invention include those depicted in Table 2. The sequences in Table 2 (SEQ ID NOS: 19-27) are exemplary, in that a phylogenetic analysis of Borrelia OspA at the indicated regions would generate additional potential sequences for use in the practice of the invention (i.e. additional sequences from other Borrelia species, strains or types).
-
TABLE 2 Example sequence variants for other epitope-containing sequences. Accession SEQ ID Epitope region Species number NO: Sequence Amino acids 17-67 B. burgdorferi NIP045688.1 19 CKQNVSSLDEKNSVSVDLPGEM KVLVSKEKNKDGKYDLIATVDK LELKGTS Amino acids 17-67 B. garinii CAA56545.1 20 CKQNVSSLDEKNSVSVDLPGGM TVLVSKEKDKDGKYSLEATVDK LELKGTS Amino acids 17-67 B. afzelii CAA59724.1 21 CKQNVSSLDEKNSASVDLPGEM KVINSKEKDKDGKYSLKATVD KIELKGTS Amino acids 94-144 B. burgdorferi NP045688.1 22 LGQTTLEVFKEDGKTLVSKKVT SKDKSSTEEKFNEKGEVSEKII TRADGTR Amino acids 94-144 B. garinii CAA56545.1 23 LSQTKFEIFKEDGKTLVSKKVT LKDKSSTEEKFNEKGETSEKTI VRANGTR Amino acids 94-144 B. afzelii CAA59724.1 24 LSKPTFELFKGDGETLVSRKVS SKDKTSTDEMFNEKGELSAKTM TRENGTK Amino acids 119-169 B. burgdorferi NP045688.1 25 KSSTEEKFNEKGEVSEKIITRA DGTRLEYTGIKSDGSGKAKEVL KGYVLEG Amino acids 119-169 B. garinii CAA56545.1 26 KSSTEEKFNEKGETSEKTIVRA NGTRLEYTDIKSDGSGKAKEVL KDFTLEG Amino acids 119-169 B. afzelii CAA59724.1 27 KTSTDEMFNEKGELSAKTMTRE NGTKLEYTEMKSDGTGKAKEVL KNFTLEG - The use of one or more these linear epitopes in vaccine preparations advantageously avoids exposing the vaccine recipient to regions of OspA that have been implicated in putative adverse vaccine effects. The inclusion of a plurality of these linear sequences provides broad coverage against the development of Lyme disease for individuals over a broad geographical area. Or, when used as a diagnostic, the polypeptides of the invention enable detection of exposure to or infection with Borrelia of most important phyletic types over a broad geographical area. Further, the vaccine and/or diagnostic compositions can be “tuned” if desired, to represent one or more, but not all, geographical regions. For example, a vaccine or diagnostic developed for use in North America might contain only sequences derived from B. burgdorferi, as this is the only species associated with Lyme disease in that geographic area. In addition, in some embodiments of the invention, polypeptides containing one or more linear OspA epitopes or antigenic regions as described herein, may also include one or more OspC epitopes or antigenic regions, as described in detail below.
- In order to facilitate the understanding of the present invention, the following definitions are provided:
- Antigen: term used historically to designate an entity that is bound by an antibody, and also to designate the entity that induces the production of the antibody. More current usage limits the meaning of antigen to that entity bound by an antibody, while the word “immunogen” is used for the entity that induces antibody production. Where an entity discussed herein is both immunogenic and antigenic, reference to it as either an immunogen or antigen will typically be made according to its intended utility. The terms “antigen”, “antigenic region” “immunogen” and “epitope” may be used interchangeably herein. As used herein, an antigen, immunogen or epitope is generally a portion of a protein (e.g. a peptide or polypeptide).
- Epitope or B-cell Epitope: a specific chemical domain on an antigen that is recognized by a B-cell receptor, and which can be bound by secreted antibody. The term as used herein is interchangeable with “antigenic determinant”.
- Immunodominant epitope: The epitope on a molecule that induces the dominant, or most intense, immune response. The immunodominant epitope would elicit the greatest antibody titer during infection or immunization, as measured by, for example, the fraction of reactivity attributable to a certain antigen or epitope in an enzyme-linked immunosorbant assay as compared with the total responsiveness to an antigen set or entire protein.
- Linear epitope: An epitope comprising a single, non-interrupted, contiguous chain of amino acids joined together by peptide bonds to form a peptide or polypeptide. Such an epitope can be described by its primary structure, i.e. the linear sequence of amino acids in the peptide chain. This is in contrast to conformational epitopes, which are comprised of at least some amino acids that are not part of an uninterrupted, linear sequence of amino acids, but which are brought into proximity to other residues in the epitope by secondary, tertiary and/or quaternary interactions of the protein. Residues in conformational epitopes may be located far from other resides in the epitope with respect to primary sequence, but may be spatially located near other residues in the conformational epitope due to protein folding.
- Protein: A linear sequence of about 100 or more amino acids covalently joined by peptide bonds.
- Polypeptide: A linear sequence of about 55 to about 100 amino acids covalently joined by peptide bonds.
- Peptide: A linear sequence of about 55 or fewer amino acids covalently joined by peptide bonds.
- Note: The terms “peptide”, “polypeptide” and “protein” may be used interchangeably herein. Chimeric or fusion peptide or polypeptide: a recombinant or synthetic peptide or polypeptide whose primary sequence comprises two or more linear amino acid sequences which do not occur together in a single molecule in nature. The two or more sequences may be, for example, a peptide (e.g. an epitope or antigenic region) and a linker sequence, or two or more peptides (which may be the same or different) which are either contiguous or separated by a linker sequences, etc.
- Original or native or wild type sequence: The sequence of a peptide, polypeptide, protein or nucleic acid as found in nature.
- Recombinant peptide, polypeptide, protein or nucleic acid: peptide, polypeptide, protein or nucleic acid that has been produced and/or manipulated using molecular biology techniques such as cloning, polymerase chain reaction (PCR), etc.
- Synthetic peptide, polypeptide, protein or nucleic acid: peptide, polypeptide, protein or nucleic acid that has been produced using chemical synthesis procedures.
- Type-specific: associated primarily with a single phyletic group.
- Invasive infection: A protein is said to be “associated with invasive infection” if a Borrelia type bearing the protein has been isolated during human infection from locations other than the skin surrounding the initial inoculation by tick bite (e.g. from plasma, cerebrospinal fluid, etc.).
- According to the invention, at least one amino acid sequence from Classes I-IV will be included in a peptide or polypeptide that is administered as a vaccine. In one embodiment of the invention, an antigenic chimeric (or fusion) polypeptide of the invention comprises one or more amino acid sequence from Class I, such as those set forth in, for example, SEQ ID NOS: 1 and 2. Usually, one or more copies of two or more Class I sequences will be included, and each distinct sequence may be present in the polypeptide one or more time, i.e. multiple copies of one or more of the sequences set forth in, for example, SEQ ID NOS: 1 and 2 are included. For example, from about 1 to about 10 of the Class I sequences may be included, and for each separate sequence that is included, that sequence may be present in from about 2 to about 12 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) or more copies. Individual copies of the sequence may be separated by linker sequences (described below), although this need not always be the case, i.e. copies of the same or different antigenic regions may be contiguous in the polypeptide chain.
- In other embodiments, one or more of the amino acid sequences set forth in or represented by the Class II or Class III or Class IV antigenic regions are included in the antigenic polypeptides of the invention. As is the case with the Class I epitopes, one or more of the peptides may be present in the antigenic polypeptide, and, for each distinct sequence that is present, multiple copies(e.g. from about 2 to about 12) may be included. Individual copies of the sequence may be separated by linker sequences, although this need not always be the case.
- In yet other embodiments, mixtures of one or more copies of one or more Class I, Class II, Class III and/or Class IV antigenic regions are present in the antigenic polypeptides of the invention. In other words, the polypeptide includes a mixture antigenic regions from any of the four classes. Each of the sequences that is included may be present in one copy or, more frequently, as multiple copies. In this type of construct, the individual sequences may be present in any order. For example, one segment or section of the polypeptide may include multiple copies of e.g. SEQ ID NO: 1, while another section of the same polypeptide includes multiple copies of e.g. SEQ ID NO: 2, and so on. Alternatively, the sequences of e.g. SEQ ID NO: 1 and e.g. SEQ ID NO: 2 may alternate along the polypeptide chain so that the sequences are, in effect, interspersed amongst each other within the primary sequence of the polypeptide.
- Other antigenic sequences of interest are those from other Borrelia proteins such as OspC. The invention thus provides chimeric polypeptides or proteins that comprise, one or more epitopes from OspC. Exemplary OspC epitopes include but are not limited to linear epitopes from the
loop 5 and/oralpha helix 5 regions. Theloop 5 region or domain of OspC is the region which includes residues that align with residues 131 to 159 of strain B31 (type A) OspC sequences (together with secondary structural elements such as a portion ofalpha helix 3,loop 5, andalpha helix 4, as defined by Kumaran et al. Thealpha helix 5 region/domain of OspC is the region which includes residues that align with amino acids 160 to 200 of the strain B31 (OspC type A) sequence and the C-terminal portion of the protein, amino acids 201-210 of the B31 sequence, as well as secondary structural elements including a portion ofloop 6,alpha helix 5, and the unstructured C-terminal domain, as defined by Kumaran et al. (2001). According to the present invention, one or more peptides encompassing epitopes located within the primary linear sequence of OspC proteins from residues 131 to 200 (using the strain B31 type A OspC sequence as a reference for residue numbering) may be included in the immunogenic polypeptides of the invention, the polypeptides of the invention. Exemplary OspC regions from which epitopes may be selected are shown inFIG. 1 , where the sequences corresponding to residues 131 to 200 of type A OspC from several Borrelia types are listed. One or more epitopes may be selected for inclusion, so that an entire 131-200 (or even 131-210 C-terminal) region encompassing several epitopes may be used. Alternatively, fragments of the 131-200 region may be employed, e.g. any contiguous sequence of from about 10 to about 50 amino acids. One or more of such contiguous sequences may be used in the practice of the invention, with preferable sequences being those corresponding to about amino acids 136 to 150 and about amino acids 168-203 ofalpha helix 5. - In particular, the general epitope locations of suitable OspC-based sequences include
Helix 3, Loop5, Loop6, Helix5 and a C-terminus sequence. Three exemplary constructs, denominated constructs A, B and C, are depicted schematically inFIGS. 2A-C (SEQ ID NOS: 62, 63 and 64). Constructs A, B and C differ in that the sequences contained therein are from different phyletic types. For example, as shown inFIG. 2A , Construct A contains sequences from Types A, B, K, I, H, N, C, M and D of B. burgdorferi. In addition, for each of Constructs A, B and C, various versions or variations have been developed. The versions differ, for example, by the inclusion or exclusion of an intervening Helix-4/Loop6 sequence, by the order of the individual epitopes, and by other exclusions and or additions, etc. Exemplary variations of Constructs A, B and C are shown in Table 3. -
TABLE 3 Number of Molecular Theoretical SEQ ID Construct amino acids weight pI NO: Construct A, version 1 569 60657.2 6.35 65 Sequence SETFTNKLKEKHTDLGKEGVTDADAKEAILKTNGTKTKGAEELGKLFESVEVLSKAAKEM <----------------------------Type A------------------------- LANSVKELTSSEEFSTKLKDNHAQLGIQGVTDENAKKAILKANAAGKDKGVEELEKLSGS ---------><-----------------------Type B-------------------- LESLSSEDFTKKLEGEHAQLGIENVTDENAKKAILITDAAKDKGAAELEKLFKAVENLAA ----><---------------------Type K------------------------->< KLKGEHTDLGKEGVTDDNAKKAILKTNNDKTKGADELEKLFESVKNLSKAAKEMLTNSSE --------------------Type I-------------------------------><- KFAGKLKNEHASLGKKDATDDDAKKAILKTHGNTDKGAKELKDLSDSVESLVSDDETKKL --------------------Type H-------------------------><------- QSSHAQLGVAGGATTDEEAKKAILRTNAIKDKGADELEKLEKSVESLAKAAQDALANSVN --------------------Type N---------------------------------- ELTSKKLKEKHTDLGKKDATDVHAKEAILKTNGTKDKGAAELEKLFESVENLAKAAKEML ---><-----------------------Type C-------------------------- SNSNKAFTDKLKSSHAELGIANGAATDANAKAAILKTNGTKDKGAQELEKLFESVKNLSK --><--------------------------Type M------------------------ AAQETLNNSSESETKKLSDNQAELGIENATDDNAKKAILKTHNAKDKGAEELVKLSESVA --------><-------------------------------Type D------------- GLLKAAQAILANSVKELTSPVVAESPKKP ----------------------------> Construct B, version 1 503 53102.4 7.16 66 Sequence SEKFTTKLKDSHAELGIQSVQDDNAKKAILKTHGTKDKGAKELEELFKSLESLSKAAQAA <------------------------------------PWa-------------------- LTNSVKELTNSDKFTKKLTDSHAQLGAVGGAINDDRAKEAILKTHGTNDKGAKELKELSE ---------><------------------------PLi---------------------- SVESLAKAAQAALANSSEAFTKKLKDSNAQLGMQNGAATDAHAKAAILKTDATKDKGATE ---------------><-------------------------PBes-------------- LGELFKSVESLSKAAQEASVAFTSKLKSSNAQLGVANGNATDDDAKKAILKTNTPNDKGA -----------------><---------------------------Pki----------- KELKELFESVESLAKAAQAALVNSVQELTNSEAFTNRLKGSHAQLGVAAATDDHAKEAIL -----------------------------><-----------------PFiM-------- KSNPTKDKGAKELKDLSESVESLAKAAQEALANSVKELTNSEAFTKKLKDNNAQLGIQNV ---------------------------------------><----------Hl3------ QDVEAKKAILKTNGDISKSEAFTNKLKEKHAELGVNGGDTTDDNAKAAIFKTHPTKDKGV -----------------><------------------Smar------------------- EDLEKLSESVKSLLKAAQAALSNSAAFTKKLQDGHVDLGKTDVTDDNAKEAILKTNPTKT ----------------------><-------------------------HT22------- KGATELEELFKSVEGLVKAAKEA ----------------------> Construct C version 1 512 54372.0 8.14 67 Sequence SEEFTNKLKSGHADLGKQDATDDHAKAAILKTHATTDKGAKEFKDLFESVEGLLKAAQVA <-------------------------------------Pko------------------- LTNSVKELTSKLKGGHAELGLAAATDENAKKAILKTNGTKDKGAEELEKLFKSVESLAKA ---------><------------------------------PLj 7-------------- AKESLTNSVKELTNTKLRDSHAELGIQNVQDDNAKRAILKTHGNKDKGAKELKELSESLE -------------><------------------PHez----------------------- KLSKAAQAALANSVQELTSSEAFTNKLKEKTQELAVAAGAATDIDAKKAILKTNRDKDLG ------------------><--------------PMit---------------------- ADERGKLFKSVESLSKAAQEASANSVKELTSSEAFTDKLKNEHASLGKKDATDDDAKKAI ------------------------------><-----------------Szid------- LKTNVDKTKGADELIKLSGSLESLSKAAQAILANSEAFTKKLQDSNADLGKHNATDADSK ---------------------------------><--------------VS461------ EAILKTNGTKTKGAKELEELFKSVESLSKAAKEALSNSVKELTSSQDFINKLKGGHAELG -------------------------------------------><--------------- LVAATDANAKAAILKTNGDKTKGADEFEKLFKSVEGLLKAAQEALTNSVKELTSSEAFTK -------HT25------------------------------------------><----- KLQDSNADLGKHDATDADAKKAILKTDATKDK -----------DK15----------------> Construct A version 2 431 46088.0 5.85 68 Sequence SETFTNKLKEKHTDLGKEGVTKGAEELGKLFESVEVLSKAAKEMLANSVKELTSSEEFST <-------Lp A---------><--------------Hx A--------------><--- KLKDNHAQLGIQGVTKGVEELEKLSGSLESLSSEDFTKKLEGEHAQLGIENVTAAELEKL ---Lp B--------><Hx B------------><--------Lp K--------><--- FKAVENLAKAAKEMAKLKGEHTDLGKEGVTKGADELEKLFESVKNLSKAAKEMLTNSKES --Hx K--------><------Lp I-----><-----------Hx I---------->< EKFAGKLKNEHASLGKKDATKGAKELKDLSDSVESLVKASDDFTKKLQSSHAQLGVAGGA -------Lp H--------><-------Hx H-------><--------Lp N------- TTADELEKLFKSVESLAKAAQDALANSVNELTSKKLKEKHTDLGKKDATAAELEKLFESV -><------------Hx N-------------><-----Lp C------><--------- ENLAKAAKEMLSNSNKAFTDKLKSSHAELGIANGAATKGAQELEKLFESVKNLSKAAQET -Hx C---------><Lp M-------------><----------------Hx M----- LNNSVKESESFTKKLSDNQAELGIENATKGAEELVKLSESVAGLLKAAQAILANSVKELT ------><--------Lp D--------><-----------------Hx D--------- SPVVAESPKKP ----------> Construct B version 2 381 39928.6 5.79 69 Sequence SEKFTTKLKDSHAELGIQSVQDKGAKELEELFKSLESLSKAAQAALTNSVKELTNSDKFT <----Lp PWa------><--------------Hx PWa---------------><---- KKLTDSHAQLGAVGGAINDKGAKELKELSESVESLAKAAQAALANSSEAFTKKLKDSNAQ -----Lp Pli------><------------Hx Pli--------><------Lp PBes LGMQNGAATDKGATELGELFKSVESLSKAAQEASVAFTSKLKSSNAQLGVANGNATDKGA --------><--------Hx PBes-------><--------Lp Pki-------><--- KELKELFESVESLAKAAQAALVNSVQELTNSEAFTNRLKGSHAQLGVAAATDKGAKELKD -------Hx Pki----------------><------Lp PFim------><-------- LSESVESLAKAAQEALANSVKELTNSEAFTKKLKDNNAQLGIQNVQSEAFTNKLKEKHAE ---Hx PFim--------------><-----Lp Hl3--------><---Lp Smar--- LGVNGGDTTDKGVEDLEKLSESVKSLLKAAQAALSNSAAFTKKLQDGHVDLGKTDVTTKG --------><----------Hx Smar---------><------Lp HT22------><-- ATELEELFKSVEGLVKAAKEA ------Hx HT22-------> Construct C version 2 383 40492.5 6.45 70 Sequence SEEFTNKLKSGHADLGKQDATKGAKEFKDLFESVEGLLKAAQVALTNSVKELTSKLKGGH <-----Lp PKo--------><---------Hx PKo----------------><---Lp AELGLAAATKGAEELEKLFKSVESLAKAAKESLTNSVKELTNTKLRDSHAELGIQNVQKG PLj7----><Hx PLj7------------------------><----Lp PHez---><- AKELKELSESLEKLSKAAQAALANSVQELTSSEAFTNKLKEKTQELAVAAGAATLGADER ---------Hx PHez--------------><-------Lp PMit-------><----- GKLFKSVESLSKAAQEASANSVKELTSSEAFTDKLKNEHASLGKKDATKGADELIKLSGS ------Hx PMit-------------><------Lp Szid------><----------- LESLSKAAQAILANSEAFTKKLQDSNADLGKHNATKGAKELEELFKSVESLSKAAKEALS Hx Szid------><------Lp VS461-----><-------------Hx VS461--- NSVKELTSSQDFINKLKGGHAELGLVAATKGADEFEKLFKSVEGLLKAAQEALTNSVKEL -------><------Lp HT25------><------------Hx HT25----------- TSSEAFTKKLQDSNADLGKHDAT -><------Lp DK15------> Construct A version 3 432 46201.2 5.85 71 Sequence SETFTNKLKEKHTDLGKEGVTKGAEELGKLFESVEVLSKAAKEMLANSVKELTSKGVEEL <--------Lp A-------><-------------Hx A--------------><----- EKLSGSLESLSNKAFTDKLKSSHAELGIANGAATKKLKEKHTDLGKKDATKGADELEKLF --Hx B----><---------Lp M---------><-----Lp C------><------- ESVKNLSKAAKEMLTNSKEIAAELEKLFKAVENLAKAAKEMAKLKGEHTDLGKEGVTSEE ----Hx I------------><--------Hx K--------><------Lp I-----> FSTKLKDNHAQLGIQGVTKGAKELKDLSDSVESLVKAAAELEKLFESVENLAKAAKEMLS <------Lp B-------><-------Hx H-------><---------Hx C------- NSSEKFAGKLKNEHASLGKKDATSEDFTKKLEGEHAQLGIENVTKGAQELEKLFESVKNL -><--------Lp H--------><--------Lp K--------><--------Hx M- SKAAQETLNNSVKEADELEKLEKSVESLAKAAQDALANSVNELTSSESETKKLSDNQAEL -------------><------------Hx N-------------><-------Lp D--- GIENATSDDFTKKLQSSHAQLGVAGGATTKGAEELVKLSESVAGLLKAAQAILANSVKEL -----><--------Lp N---------><--------------------Hx D------ TSPVVAESPKKP -----------> Construct B version 3 382 40056.8 5.93 72 Sequence SEAFTKKLKDSNAQLGMQNGAATDKGAKELEELEKSLESLSKAAQAALTNSVKELTNKDK <----------Lp PBes----><-------------Hx PWa-------------><-- GAKELKELFESVESLAKAAQAALVNSVQELTNSEKETTKLKDSHAELGIQSVQSDKFTKK --------Hx PKi-----------------><------Lp PWa-------><------ LTDSHAQLGAVGGAINDKGAKELKELSESVESLAKAAQAALANSDKGAKELKDLSESVES -Lp Pli--------><----------Hx Pli----------><-------------Hx LAKAAQEALANSVKELTNSVAFTSKLKSSNAQLGVANGNATSEAFTKKLKDNNAQLGIQN PFim-------------><------Lp PKi---------><------Lp H13------ VQTKGATELEELFKSVEGLVKAAKEADKGVEDLEKLSESVKSLLKAAQAALSNSAAFTKK -><--------Hx HT22-------><----------Hx Smar--------><------ LQDGHVDLGKTDVTSEAFTNRLKGSHAQLGVAAATDKGATELGELFKSVESLSKAAQEAS Lp HT22------><-----Lp PFim-------><-------Hx PBes-------->< EAFTNKLKEKHAELGVNGGDTT -------Lp Smar-------> Construct C version 3 383 40622.6 6.10 73 Sequence SEEFTNKLKSGHADLGKQDATKGAKEFKDLFESVEGLLKAAQVALTNSVKELTSKEKGAE <------Lp PKo-------><-------------Hx PKo-------------><---- ELEKLFKSVESLAKAAKESLTNSVKELTNSEAFTDKLKNEHASLGKKDATTKLRDSHAEL ----Hx PLj------------------><-----Lp Szid-------><-------Lp GIQNVQLGADERGKLFKSVESLSKAAQEASANSVKELTSKEKGAKELEELFKSVESLSKA PHez-><------------Hx PMit--------><---------------Hx VS461- AKEALSNSVKELTSSEAFTKKLQDSNADLGKHNATSEAFTKKLQDSNADLGKHDATKGAD -------------><------Lp VS461-----><-------Lp DK15-----><--- EFEKLFKSVEGLLKAAQEALTNSVKELTSELKELSESLEKLSKAAQAALANSVQELTSSE -------Hx HT25--------------><-----------Hx PHez---------><- AFTNKLKEKTQELAVAAGAATKLKGGHAELGLAAATKGADELIKLSGSLESLSKAAQAIL -----Lp PMit--------><---Lp PLj7---><---------Hx Szid------- ANSQDFINKLKGGHAELGLVAAT -><-----Lp HT25-------> - In some embodiments, at least two of the OspC epitopes included in the chimeric polypeptide are from different OspC types that are associated with invasive infection. For example, antigenic epitopes representing from about 2 to about 20, and preferably from about 6 to about 10, different OspC types are included in a chimeric protein. When used as a vaccine, such a multivalent (polyvalent) recombinant chimeric protein elicits broad protection against infection with Borrelia spirochetes expressing the OspC types that correspond to those in the chimeric protein, i.e. those Borrelia that are highly infective. While typically at least two of the epitopes are different from one another in primary sequence and originate from different OspC types, it is also possible to include multiple copies of a single type of OspC epitope in a chimera, or to include several sequences that are based on or derived from the original sequence of the same OspC type. While the total number of linear OspC epitopes in a chimera may vary somewhat, in general, the range will be from about 10 to about 20. In one embodiment of the invention, the immunodominant OspC epitopes are selected from OspC types Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A,72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, C. Those of skill in the art will recognize that epitopes from many combinations of OspC types may be used, so long as the resulting chimera produces a suitable immune response and/or is effective as a vaccine in preventing Lyme disease. Examples of suitable combinations of OspC epitopes (which may optionally be combined with OspA epitopes of Classes I-IV) include but are not limited to: 1) E, N, I, C, A, B, K, D; 2) A, B, K, D, E, N, C; 3) I, C, A, B, K, D; and 4) C, A, B, K, D.
- In some embodiments, both the
OspC loop 5 andOspC alpha helix 5 regions will be included. For example, an “E, N, I, C, A, B, K, D” construct may contain both theloop 5 andhelix 5 regions of each of OspC types E, N, I, C, A, B, K, and D. However, this need not be the case. For example, theloop 5 region of type A and thealpha helix 5 regions of E, N, I, C, B, K, and D may be included; or only theloop 5 region for each OspC type may be included; or only thealpha helix 5 region; or other combinations may be included (e.g. loop 5 region of types E, N, I, and C and thealpha helix 5 region of types A, B, K, and D. Many such combinations will occur to those of skill in the art, and all such variations are intended to be encompassed herein. - In other embodiments of the invention, one or more of the sequences represented by OspA Classes I-IV are present in an antigenic polypeptide which also includes antigenic sequences of OspC as described above.
- In addition, other peptide sequences may be included in the peptides and polypeptides of the invention. Such sequences include but are not limited to antigenic peptide sequences such as linker sequences which in and of themselves are antigenic.
- Those of skill in the art will recognize that, while in some embodiments of the invention, the amino acid sequences that are chosen for inclusion in the peptides and polypeptides of the invention correspond exactly to the primary amino acid sequence of the original or native sequences of an OspA (or OspC) protein, this need not always be the case. The amino acid sequence of an epitope that is included in the peptides and polypeptides of the invention may be altered somewhat and still be suitable for use in the present invention. For example, certain conservative amino acid substitutions may be made without having a deleterious effect on the ability of the peptides and polypeptides to elicit an immune response. Those of skill in the art will recognize the nature of such conservative substitutions, for example, substitution of a positively charged amino acid for another positively charged amino acid (e.g. K for R or vice versa); substitution of a negatively charged amino acid for another negatively charged amino acid (e.g. D for E or vice versa); substitution of a hydrophobic amino acid for another hydrophobic amino acid (e.g. substitution of A, V, L, I, W, etc. for one another); etc. All such substitutions or alterations of the sequences of the peptides and polypeptides that are disclosed herein are intended to be encompassed by the present invention, so long as the resulting peptides and polypeptides still function to elicit a suitable immune response. In addition, the amino acid sequences that are included in the chimeric proteins of the invention need not encompass a full length native peptide or polypeptide. Those of skill in the art will recognize that truncated versions of amino acid sequences that are known to be or to contain antigenic peptides and/or polypeptides may, for a variety of reasons, be preferable for use in the practice of the invention, so long as the criteria set forth for an epitope is fulfilled by the sequence. Amino acid sequences that are so substituted or otherwise altered may be referred to herein as “based on” or “derived from” the original wild type or native sequence. In general, the OspA or OspC proteins from which the linear epitopes are “derived” or on which the linear epitopes are “based” are the OspA or OspC proteins as they occur in nature. These natural OspA/OspC proteins may alternatively be referred to as native or wildtype proteins.
- Such changes to the primary sequence may be introduced for any of a variety of reasons, for example, to eliminate or introduce a protease cleavage site, to increase or decrease solubility, to promote or discourage intra- or inter-molecular interactions such as folding, ionic interactions, salt bridges, etc, which might otherwise interfere with the presentation and accessibility of the individual epitopes along the length of a peptide or polypeptide. All such changes are intended to be encompassed by the present invention, so long as the resulting amino acid sequence functions to elicit a protective antibody response in a host to whom it is administered. In general, such substituted sequences will be at least about 50% identical to the corresponding sequence in the native protein, preferably about 60 to 70, or even 70 to 80, or 80 to 90% identical to the wild type sequence, and preferably about 95, 96, 97, 98, 99, or even 100% identical to a native OspA (or OspC) sequence. The reference native OspA or OspC sequence may be from any suitable type of Borrelia, e.g. from any Borrelia which is known to infect mammals.
- In some embodiments of the invention, the individual linear epitopes in the chimeric vaccinogen are separated from one another by intervening sequences that are more or less neutral in character, i.e. they do not in and of themselves elicit an immune response to Borrelia. Such sequences may or may not be present between the epitopes of a chimera. If present, they may, for example, serve to separate the epitopes and contribute to the steric isolation of the epitopes from each other. Alternatively, such sequences may be simply artifacts of recombinant processing procedures, e.g. cloning procedures. Such sequences are typically known as linker or spacer peptides, many examples of which are known to those of skill in the art. See, for example, Crasto, C. J. and J. A. Feng. 2000. LINKER: a program to generate linker sequences for fusion proteins. Protein Engineering 13(5): 309-312, which is a reference that describes unstructured linkers. Structured (e.g. helical) sequence linkers may also be designed using, for example, existing sequences that are known to have that secondary structure, or using basic known biochemical principles to design the linkers. In addition, other elements may be present in the chimeric proteins, for example leader sequences or sequences that “tag” the protein to facilitate purification or detection of the protein, examples of which include but are not limited to histidine tags, detection tags (e.g. S-tag, or Flag-tag), other antigenic amino acid sequences such as known T-cell epitope containing sequences and protein stabilizing motifs, etc. In addition, the chimeric proteins may be chemically modified, e.g. by amidation, sulfonylation, lipidation, or other techniques that are known to those of skill in the art.
- The invention further provides nucleic acid sequences that encode the chimeric proteins of the invention. Such nucleic acids include DNA, RNA, and hybrids thereof, and the like. Further, the invention comprehends vectors which contain or house such coding sequences. Examples of suitable vectors include but are not limited to plasmids, cosmids, viral based vectors, expression vectors, etc. In a preferred embodiment, the vector will be a plasmid expression vector.
- The chimeric polypeptides of the invention may be produced by any suitable method, many of which are known to those of skill in the art. For example, they may be chemically synthesized, or produced using recombinant DNA technology (e.g. in bacterial cells, in cell culture (mammalian, yeast or insect cells), in plants or plant cells, or by cell-free prokaryotic or eukaryotic-based expression systems, by other in vitro systems, etc.). In some embodiments, the polypeptides are produced using chemical synthesis methods.
- The present invention also provides compositions for use in eliciting an immune response. The compositions may be utilized as vaccines to prevent or treat Borrelia infection, particularly when manifested as Lyme disease (Lyme borreliosis). By eliciting an immune response, we mean that administration of the antigen causes the synthesis of specific antibodies (at a titer as described above) and/or cellular proliferation, as measured, e.g. by 3H thymidine incorporation, or by other known techniques. By “vaccine” we mean a chimeric or fusion polypeptide that elicits an immune response which results in protection of an organicism against challenge with Borrelia. The protective response either wholly or partially prevents or arrests the development of symptoms related to Borrelia infection (i.e. the symptoms of Lyme disease), in comparison to a non-vaccinated (e.g. adjunct alone) control organisms, in which disease progression is not prevented. The compositions include one or more isolated and substantially purified chimeric peptides or polypeptides as described herein, and a pharmacologically suitable carrier. The chimeric polypeptides or proteins in the composition may be the same or different, i.e. the composition may be a “cocktail” of different chimeras, or a composition containing only a single type of chimera. The preparation of such compositions for use as vaccines is well known to those of skill in the art. Typically, such compositions are prepared either as liquid solutions or suspensions, however solid forms such as tablets, pills, powders and the like are also contemplated. Solid forms suitable for solution in, or suspension in, liquids prior to administration may also be prepared. The preparation may also be emulsified. The active ingredients may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredients. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like, or combinations thereof. In addition, the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like. The vaccine preparations of the present invention may further comprise an adjuvant, suitable examples of which include but are not limited to Seppic, Quil A, Alhydrogel, etc. If it is desired to administer an oral form of the composition, various thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders and the like may be added. The composition of the present invention may contain any such additional ingredients so as to provide the composition in a form suitable for administration. The final amount of chimeric protein in the formulations may vary. However, in general, the amount in the formulations will be from about 0.01-99%, weight/volume.
- The methods involve administering a composition comprising a chimeric recombinant protein in a pharmacologically acceptable carrier to a mammal. The mammal may be a human, but this need not always be the case, as veterinary applications of this technology are also contemplated. The vaccine preparations of the present invention may be administered by any of the many suitable means which are well known to those of skill in the art, including but not limited to by injection, inhalation, orally, intranasally, by ingestion of a food product containing the chimeric protein, etc. In preferred embodiments, the mode of administration is subcutaneous or intramuscular. In addition, the compositions may be administered in conjunction with other treatment modalities such as substances that boost the immune system, various anti-bacterial chemotherapeutic agents, antibiotics, and the like.
- The present invention provides methods to elicit an immune response to Borrelia and to vaccinate against Borrelia infection in mammals. In one embodiment, the mammal is a human However, those of skill in the art will recognize that other mammals exist for which such vaccinations would also be desirable, e.g. the preparations may also be used for veterinary purposes. Examples include but are not limited to companion “pets” such as dogs, cats, etc.; food source, work and recreational animals such as cattle, horses, oxen, sheep, pigs, goats, and the like; or even wild animals that serve as a reservoir of Borrelia (e.g. mice, deer, etc).
- The invention also provides a diagnostic and a method for using the diagnostic to identify individuals who have antibodies to the epitopes contained within the chimeric polypeptides of the invention. A biological sample from an individual (e.g. a human, a deer, or other mammals susceptible to infection by Borrelia spirochetes) suspected of having been exposed to Borrelia, or at risk for being exposed to Borrelia, is contacted with the chimeric proteins of the invention. Using known methodology, the presence or absence of a binding reaction between the chimeric protein and antibodies in the biological sample is detected. A positive result (i.e. binding occurs, thus antibodies are present) indicates that the individual has been exposed to and/or is infected with Borrelia. Further, the diagnostic aspects of the invention are not confined to clinical use or home use, but may also be valuable for use in the laboratory as a research tool, e.g. to identify Borrelia spirochetes isolated from ticks, to investigate the geographical distribution of Borrelia species and strains, etc.
- The present invention also encompasses antibodies to the epitopes and/or to the chimeric polypeptides disclosed herein. Such antibodies may be polyclonal, monoclonal or chimeric, and may be generated in any manner known to those of skill in the art. In a preferred embodiment of the invention, the antibodies are bactericidal (borrelia cidal), i.e. exposure of Borrelia spirochetes to the antibodies causes death of the spirochetes. Such antibodies may be used in a variety of ways, e.g. as detection reagents to diagnose prior exposure to Borrelia, as a reagent in a kit for the investigation of Borrelia, to treat Borrelia infections, etc.
- Alternatively, appropriate antigen fragments or antigenic sequences or epitopes may be identified by their ability, when included in a chimeric protein, to elicit suitable antibody production to the epitope in a host to which the chimeric protein is administered. Those of skill in the art will recognize that definitions of antibody titer may vary. Herein, “titer” is taken to be the inverse dilution of antiserum that will bind one half of the available binding sites on an ELISA well coated with 100 ng of test protein. In general, suitable antibody production is characterized by an antibody titer in the range of from about 100 to about 100,000, and preferably in the range of from about 10,000 to about 10,000,000. Alternatively, and particularly in diagnostic assays, the “titer” should be about three times the background level of binding. For example, to be considered “positive”, reactivity in a test should be at least three times greater than reactivity detected in serum from uninfected individuals. Preferably, the antibody response is protective, i.e. prevents or lessens the development of symptoms of disease in a vaccinated host that is later exposed to Borrelia, compared to an unvaccinated host.
- The following Examples are provided to illustrate various embodiments of the invention, but should not be considered as limiting in any way.
- Recombinant protein production
- Fragments of the outer surface protein A (OspA) gene were amplified by PCR using high fidelity DNA polymerase (Phusion HF, New England Biolabs), and the amplicons purified by agarose gel electrophoresis and gel extraction. Overhangs were generated by treatment with T4 polymerase to allow ligase-independent annealing to the pET-32 Ek/LIC vector. The annealed vector was transformed into Escherichia coli, and the transformants were selected for ampicillin resistance, and were screened for the presence of the OspA gene fragment by PCR. Plasmids were then extracted from the transformants and the sequence confirmed by DNA sequencing (MWG Biotech). The plasmids were then used to transform E. coli BL21 (DE3) cells for protein production.
- To generate recombinant proteins, BL21(DE3) cells were grown at 37° C. to an OD600 of 0.5, then 1 mM IPTG was added to induce protein expression, and the cells were maintained at 37° C. for an additional 3 hours. The pET-32 Ek/LIC vector encodes a 17.1 kDa N-terminal protein tagging sequence which includes a hexahistidine motif that was used to purify the r-proteins by Ni—NTA nickel affinity chromatography, according to the manufacturer's protocol (Qiagen). The purified proteins were quantified by the bicinchoninic acid assay (Pierce).
- Borrelia burgdorferi strains B31MI, LDP74, and B331 were grown to late log phase in BSK-H medium (Sigma). The cells were washed with fresh medium, quantified by microscopy, and diluted in BSK-H medium to 104 cells per 0.1 mL of medium. Strain C3H/HeJ mice were infected with 104 cells by subcutaneous injection between the scapulae, with 5 mice infected with each spirochete strain. The mice were bled at
week 6 by tail nick, and infection was confirmed by culture of a 2 mm ear punch biopsy. Serum was prepared from the infected mouse blood samples, and will be referred to hereafter as infection serum. - To map linear B-cell epitopes, overlapping recombinant subfragments of OspA were separated by 15% SDS-PAGE and blotted to PVDF. The membranes were blocked with 5% NFDM in PBS-T, and probed with mouse infection sera (1:500 dilution). To assess equality of protein loading, one blot was probed with a mouse monoclonal antibody specific to the hexahistidine motif in the expression tag sequence. The blots were then washed and probed with peroxidase-conjugated goat-anti-mouse IgG antiserum (1:20000; Pierce). The blots were washed, incubated with a chemiluminescent substrate (Supersignal West Pico; Pierce), and exposed to film. When reactive OspA fragments were determined, a series of smaller overlapping subfragments was made to further resolve the location of the linear epitope (
FIG. 3 ). - The full length ospA gene from the Borrelia strains used to produce infection sera were PCR amplified and cloned into the pET-46 Ek/LIC vector as described above, and the DNA sequences were aligned and compared. In addition, the 204 full length OspA sequences from the Lyme spirochetes B. burgdorferi, B. garinii, and B. afzelii that are available in the NCBI databases were aligned and analyzed for polymorphisms in the epitope containing regions. This was done by multisequence alignment using ClustalX, and generation of neighbor joining phylogenetic trees. These analyses were done on the full length OspA gene, as well as on the epitope-containing subfragments. Once the alignments and trees were complete, representative sequences were extracted that demonstrate extant sequence variants, which may correspond to antigenic variants. Analytical tools included ClustalX, Bioedit, and TreeView.
- A western blot-based search for linear B-cell epitopes on OspA revealed several amino acid sequences that were reactive with antibodies generated during murine infection (
FIG. 4 ). The reactive subfragments are located at the N-terminus (amino acids 17-67; noted in a single mouse), within a central single layer beta-sheet (amino acids 94-144, and 119-169; seen in multiple mice), and within a membrane-distal loop (amino acids 194-246 and 220-273; highly reactive in multiple mice). High resolution mapping of the beta-sheet epitope containing region failed to further localize the epitope. The most reactive linear epitope was found in the membrane distal loop, and subsequent high resolution mapping localized it to amino acids 221-240. The pattern of reactivity varied somewhat in intensity between mice, but was observed in sera from mice infected with each of the three test Borrelia strains. - Comparison of sequences among the three Borrelia strains used to infect mice revealed either one or two amino acid differences among them, at amino acid positions 39 (K/N) and 149 (G/E) (
FIG. 5 ). An analysis of available OspA sequences demonstrated several major clades, which split primarily along species lines (B. burgdorferi, B. garinii, and B. afzelii). To better understand the impact of the clades on the development of an epitope-based vaccine, the 221-240 region was analyzed separately, aligned, and a neighbor joining tree created. This also demonstrated the presence of distinct clades of this epitope containing region, again separated primarily by species. There were 2 predominant epitope region sequences within B. burgdorferi, 5 within B. garinii, and 1 within B. afzelii derived OspA sequences. The 221-240 amino acid regions in each of these predominant groups is shown in Table 1. Representative alignments of the other three epitope-containing sequences are shown in Table 2. Using the methods described above, the potential variants of these epitopes can be easily analyzed. - The mapping of novel linear B-cell epitopes in OspA represents a significant advance in the development of second-generation Lyme disease vaccines. Previous research has primarily focused on known conformational epitopes, primarily the epitope recognized by the LA-2 monoclonal antibody. Linear OspA epitopes have been described, however, this study is novel in its use of serum derived from mice infected with clonal Borrelia populations. The similar epitope recognition pattern during infection with three distinct Borrelia burgdorferi strains further supports the relevance of these epitope containing regions during infection. While OspA is expressed during in vitro culture, it is normally downregulated upon exposure to the mammalian environment or during the tick blood meal during the normal enzootic cycle. Because of this regulation, it is likely that the OspA protein was expressed only for a short time during the infection, which may account for the variability in the intensity of responsiveness between mice. This apparent variability may be enhanced by the IgG-specific screening technique, requiring the B-cells of the infected mice to progress to a more mature immune response and undergo immunoglobulin heavy chain class switching.
- The large degree of intraspecies conservation at the mapped epitope-containing regions is of particular advantage in development of a peptide or chimeric vaccine. For example, since B. burgdorferi is the only species associated with Lyme disease in North America, the occurrence of only a limited number of phylogenetic clades of OspA is particularly advantageous. At the epitope level, the number of major clades is also limited, with only two major antigenically distinct clades representing the large majority of the 221-240 epitope containing region. Borrelia afzelii, which occurs only in Europe and Asia, is limited to a single clade at this region, and B. garinii has approximately 6 clades, several of which are closely related, though it is not yet known if they are antigenically cross-reactive. It is clear that in order for broad protection to be achieved by a peptide vaccine approach, the use of a single OspA epitope sequence is not possible. For that reason, the development of a multi-epitope chimeric vaccine based on OspA epitope variants or on a combination of epitope variants of OspA and OspC is highly desirable. In addition, a significant advantage to the use of defined epitope containing sequences is the ability to avoid segments of the OspA molecule that have been reported to be associated with development of autoimmune responses. While there is disagreement in the literature as to the incidence of these responses caused by anti-OspA antibodies or anti-OspA immune responses, it is advantageous to avoid those portions of OspA that have been implicated (
FIG. 6 ). - When administered to test mammals, this chimeric polypeptide construct comprising at least one 221-240 epitope containing region, and usually two or more 221-240 epitope containing regions from of different phyletic types, is found to elicit a robust immune response, and to provide protection from the development of Lyme disease.
- While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.
Claims (19)
1. An isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
2. The isolated recombinant or synthetic peptide or polypeptide of claim 1 , wherein said at least one linear epitope is selected from the group consisting of
3. The isolated recombinant or synthetic peptide or polypeptide of claim 1 , further comprising one or more amino acid sequences that are epitopes of Borrelia outer surface protein C (OspC).
4. The isolated recombinant or synthetic peptide or polypeptide of claim 3 , wherein said one or more amino acid sequences that are epitopes of Borrelia OspC are from an OspC loop 5 region or an OspC alpha helix 5 region, or both.
5. The isolated recombinant or synthetic peptide or polypeptide of claim 3 , wherein said one or more amino acid sequences that are epitopes of OspC are from OspC types selected from the group consisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A,72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, and C.
6. The isolated recombinant or synthetic peptide or polypeptide of claim 3 , wherein said one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73.
7. A method for eliciting an immune response against Borrelia in an individual in need thereof, comprising the step of
administering to said individual an isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
8. The method of claim 7 , wherein said at least one linear epitope has an amino acid sequence selected from the group consisting of
9. The method of claim 7 , wherein said isolated recombinant or synthetic peptide or polypeptide further comprises one or more epitopes of Borrelia outer surface protein C (OspC).
10. The method of claim 9 , wherein said one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73.
11. A method for ascertaining whether an individual has been exposed to or infected with Borrelia, or both, comprising the steps of
obtaining a biological sample from said individual,
exposing said biological sample to a recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
and
determining whether antibodies in said biological sample bind to said recombinant or synthetic peptide or polypeptide, wherein detection of antibody binding is indicative of prior exposure to or infection with Borrelia.
12. The method of claim 11 , wherein said recombinant or synthetic peptide or polypeptide further comprises one or more epitopes of Borrelia outer surface protein C (OspC).
13. The method of claim 12 , wherein said one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73.
14. An antibody to a recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
15. The antibody of claim 19 , wherein said antibody is bactericidal for Borrelia spirochetes.
16. An isolated recombinant or synthetic peptide or polypeptide comprising one or more epitopes from Borrelia outer surface protein A (OspA), said one or more epitopes being from an antigenic region selected from the group consisting of: antigenic region 221-240, antigenic region 17-67, antigenic region 94-144, and antigenic region 119-169.
17. The isolated recombinant or synthetic peptide or polypeptide of claim 16 , further comprising one or more epitopes of Borrelia outer surface protein C (OspC).
18. An isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein C (OspC), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
19. The isolated recombinant or synthetic peptide or polypeptide of claim 18 , further comprising one or more epitopes of Borrelia outer surface protein A (OspA).
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/990,079 US20110262475A1 (en) | 2008-05-02 | 2009-05-01 | Lyme disease vaccine |
US14/243,476 US9534021B2 (en) | 2008-05-02 | 2014-04-02 | Lyme disease vaccine |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5003408P | 2008-05-02 | 2008-05-02 | |
PCT/US2009/042513 WO2009135118A2 (en) | 2008-05-02 | 2009-05-01 | Lyme disease vaccine |
US12/990,079 US20110262475A1 (en) | 2008-05-02 | 2009-05-01 | Lyme disease vaccine |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/042513 A-371-Of-International WO2009135118A2 (en) | 2008-05-02 | 2009-05-01 | Lyme disease vaccine |
PCT/US2009/004253 A-371-Of-International WO2010014169A2 (en) | 2008-08-01 | 2009-07-21 | Knit ptfe articles and mesh |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/243,476 Continuation US9534021B2 (en) | 2008-05-02 | 2014-04-02 | Lyme disease vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110262475A1 true US20110262475A1 (en) | 2011-10-27 |
Family
ID=41255853
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/990,079 Abandoned US20110262475A1 (en) | 2008-05-02 | 2009-05-01 | Lyme disease vaccine |
US14/243,476 Expired - Fee Related US9534021B2 (en) | 2008-05-02 | 2014-04-02 | Lyme disease vaccine |
US15/361,162 Expired - Fee Related US10266571B2 (en) | 2008-05-02 | 2016-11-25 | Lyme disease vaccine |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/243,476 Expired - Fee Related US9534021B2 (en) | 2008-05-02 | 2014-04-02 | Lyme disease vaccine |
US15/361,162 Expired - Fee Related US10266571B2 (en) | 2008-05-02 | 2016-11-25 | Lyme disease vaccine |
Country Status (3)
Country | Link |
---|---|
US (3) | US20110262475A1 (en) |
EP (1) | EP2283031B1 (en) |
WO (1) | WO2009135118A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016025331A1 (en) | 2014-08-11 | 2016-02-18 | University Of Massachusetts | Anti-ospa antibodies and methods of use |
US9562079B2 (en) | 2012-04-18 | 2017-02-07 | Zoetis Services Llc | Vaccines and methods to treat lyme disease in dogs |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2569009T3 (en) | 2010-05-14 | 2020-06-15 | Baxalta Incorporated | Ospa chimeras and use thereof in vaccines |
US20160097768A1 (en) | 2010-10-20 | 2016-04-07 | Virginia Commonwealth University | Polyvalent chimeric ospc vaccinogen and diagnostic antigen |
CA2815279C (en) | 2010-10-20 | 2021-04-13 | Virginia Commonwealth University | Polyvalent chimeric ospc vaccinogen and diagnostic antigen |
CA2863661C (en) * | 2012-02-01 | 2021-06-01 | Biopeptides Corp | Diagnostic peptides for lyme disease |
UY34745A (en) * | 2012-04-18 | 2013-11-29 | Zoetis Llc | VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS |
KR20150038380A (en) | 2012-07-27 | 2015-04-08 | 백스터 인터내셔널 인코포레이티드 | Compositions comprising chimeric ospa molecules and methods of use thereof |
WO2016057793A1 (en) * | 2014-10-08 | 2016-04-14 | Virginia Commonwealth University | Stage specific diagnostic antigens, assay and vaccine for lyme disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070178117A1 (en) * | 2005-11-29 | 2007-08-02 | Marconi Richard T | Polyvalent Chimeric OspC Vaccinogen and Diagnostic Antigen |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0536335A4 (en) | 1990-06-15 | 1993-07-14 | Yale University | Compositions and methods for the prevention and diagnosis of lyme disease |
CA2057536C (en) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Cloning and expression of borrelia lipoproteins |
US6872550B1 (en) | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US6210676B1 (en) * | 1998-07-31 | 2001-04-03 | Gundersen Lutheran Medical Foundation | Compositions and methods using the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein C (OspC) for the diagnosis and prevention of lyme disease |
AU2001285049A1 (en) * | 2000-08-18 | 2002-03-04 | Brookhaven Sciences Associates, Llc | Altered ospa of borrelia burgdorferi |
US6570379B2 (en) | 2000-08-24 | 2003-05-27 | Shell Oil Company | Method for inspecting an object of electrically conducting material |
-
2009
- 2009-05-01 WO PCT/US2009/042513 patent/WO2009135118A2/en active Application Filing
- 2009-05-01 US US12/990,079 patent/US20110262475A1/en not_active Abandoned
- 2009-05-01 EP EP09739920.8A patent/EP2283031B1/en not_active Not-in-force
-
2014
- 2014-04-02 US US14/243,476 patent/US9534021B2/en not_active Expired - Fee Related
-
2016
- 2016-11-25 US US15/361,162 patent/US10266571B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070178117A1 (en) * | 2005-11-29 | 2007-08-02 | Marconi Richard T | Polyvalent Chimeric OspC Vaccinogen and Diagnostic Antigen |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9562079B2 (en) | 2012-04-18 | 2017-02-07 | Zoetis Services Llc | Vaccines and methods to treat lyme disease in dogs |
WO2016025331A1 (en) | 2014-08-11 | 2016-02-18 | University Of Massachusetts | Anti-ospa antibodies and methods of use |
US10457721B2 (en) | 2014-08-11 | 2019-10-29 | University Of Massachusetts | Anti-OSPA antibodies and methods of use |
EP4108256A1 (en) * | 2014-08-11 | 2022-12-28 | University of Massachusetts | Anti-ospa antibodies and methods of use |
Also Published As
Publication number | Publication date |
---|---|
WO2009135118A9 (en) | 2010-04-15 |
EP2283031A4 (en) | 2011-09-21 |
US9534021B2 (en) | 2017-01-03 |
US10266571B2 (en) | 2019-04-23 |
EP2283031B1 (en) | 2017-04-12 |
US20140212451A1 (en) | 2014-07-31 |
EP2283031A2 (en) | 2011-02-16 |
US20170114106A1 (en) | 2017-04-27 |
WO2009135118A3 (en) | 2010-02-25 |
WO2009135118A2 (en) | 2009-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10266571B2 (en) | Lyme disease vaccine | |
Comstedt et al. | Design and development of a novel vaccine for protection against Lyme borreliosis | |
Noordhoek et al. | A new attempt to distinguish serologically the subspecies of Treponema pallidum causing syphilis and yaws | |
Oliver Jr et al. | Antibody profiling of canine IgG responses to the OspC protein of the Lyme disease spirochetes supports a multivalent approach in vaccine and diagnostic assay development | |
CZ289212B6 (en) | Immunogenic preparation against Lyme disease, recombinant DNA sequences, OspC antigen, use of antigen combination and method of recombinant production of the OspC antigen | |
CA2969430A1 (en) | Enzyme-linked immunosorbent assay (elisa) for the detection of anti-mycoplasma hyorhinis igg in swine serum | |
KR20130125771A (en) | Polyvalent chimeric ospc vaccinogen and diagnostic antigen | |
US8895021B2 (en) | Sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof | |
US20220152180A1 (en) | Chimeric vaccine antigens for anaplasmosis | |
WO2010132758A2 (en) | Ospc-based diagnostic test for lyme disease | |
US10086057B2 (en) | Stage specific diagnostic antigens, assay and vaccine for lyme disease | |
US20110064761A1 (en) | Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof | |
EP1240328B1 (en) | Antigenic protein lppq of mycoplasma mycoides subsp. mycoides sc., its preparation and use | |
US11899015B1 (en) | Chimeric recombinant proteins and recombinant protein panels for the diagnosis of Lyme disease in animals and humans | |
US20140248272A1 (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
EP2024497A2 (en) | Liga and ligb proteins (leptospiral ig-like (lig) domains) for vaccination and diagnosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VIRGINIA COMMONWEALTH UNIVERSITY, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EARNHART, CHRISTOPHER G.;MARCONI, RICHARD T.;REEL/FRAME:025212/0110 Effective date: 20101027 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |